



THE COCHRANE LIBRARY

Independent high-quality evidence for health care decision making

The Cochrane Library. The single most reliable source of evidence in healthcare
The Cochrane Reviews highlighted below are available from the
Cochrane Database of Systematic Reviews (www.thecochranelibrary.com)
Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback,
and the Cochrane Database of Systematic Reviews should always be consulted for the most recent version of the review.

CAN PROBIOTICS PLUS VITAMIN D SUPPLEMENTS BENEFIT PEOPLE WITH SCHIZOPHRENIA?

APRIL 10, 2024 - Previous studies have questioned whether gut microbe imbalances and vitamin D deficiency may be linked to schizophrenia. New research published in *Neuropsychopharmacology Reports* now indicates that taking probiotics plus vitamin D supplements may improve cognitive function in individuals with the disease.

For the study, 70 adults with schizophrenia were randomized to take a placebo or probiotic supplements plus 400 IU vitamin D daily for 12 weeks. Severity of the disease and cognitive function were evaluated by tests called the Positive and Negative Syndrome Scale (PANSS) and the 30-point Montreal Cognitive Assessment (MoCA), respectively.

A total of 69 patients completed the study. The MoCA score increased by 1.96 units in the probiotic-containing supplement group compared with the placebo group. Also, the percentage of patients with MoCA scores of 26 or higher (indicating normal cognition) rose significantly in the intervention group. Between-group differences in PANSS scores were not significant.

“Probiotics may be a novel way to treat mental disorders by regulating gut microbiota,” said corresponding author Gita Sadighi, MD, of the University of Social Welfare and Rehabilitation Sciences, in Iran.

URL upon publication: <https://onlinelibrary.wiley.com/doi/10.1002/npr2.12431>

Full citation: “Co-administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double-blinded randomized controlled trial.” Aida Mohammadi, Gita Sadighi, Ali Nazeri Astaneh, Maryam Tajabadi-Ebrahimi, Tahereh Dejam. *Neuropsychopharmacology Reports*; Published Online: 10 April 2024 (DOI: 10.1002/npr2.12431).

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd., reproduced with permission.